Company news

TScan Therapeutics, Inc. news in 2024

TScan Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

December 25, 2024

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

December 22, 2024

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 11, 2024

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

November 4, 2024

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

October 3, 2024

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 11, 2024

TScan Therapeutics Announces Updates to its Board of Directors

June 13, 2024

TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 28, 2024

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 12, 2024

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

May 8, 2024

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

April 23, 2024

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

April 23, 2024

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

April 21, 2024

TScan Therapeutics Announces Closing of Upsized Public Offering

April 18, 2024

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

April 16, 2024

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

April 15, 2024

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

April 7, 2024

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

April 1, 2024

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 5, 2024

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

February 25, 2024

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

February 5, 2024

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

January 28, 2024

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

January 17, 2024

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

January 3, 2024

Decks in 2024